Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Current Assets (2022 - 2025)

Oramed Pharmaceuticals' Current Assets history spans 4 years, with the latest figure at $133.3 million for Q4 2025.

  • For Q4 2025, Current Assets changed N/A year-over-year to $133.3 million; the TTM value through Dec 2025 reached $133.3 million, changed N/A, while the annual FY2025 figure was $133.3 million, N/A changed from the prior year.
  • Current Assets reached $133.3 million in Q4 2025 per ORMP's latest filing, down from $136.1 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $177.1 million in Q1 2024 to a low of $99.0 million in Q2 2025.
  • Average Current Assets over 4 years is $147.5 million, with a median of $151.0 million recorded in 2023.
  • Peak YoY movement for Current Assets: rose 14.14% in 2024, then tumbled 35.39% in 2025.
  • A 4-year view of Current Assets shows it stood at $157.1 million in 2022, then rose by 3.48% to $162.6 million in 2023, then dropped by 12.18% to $142.8 million in 2024, then decreased by 6.66% to $133.3 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Current Assets are $133.3 million (Q4 2025), $136.1 million (Q3 2025), and $99.0 million (Q2 2025).